Table 3.
Demographic data for the patients categorized according to rabeprazole treatment day
| Day 1 | Day 4 | Day 7 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| CYP2C19 | HomEM | HetEM | PM | HomEM | HetEM | PM | HomEM | HetEM | PM |
| No. | 13 | 14 | 5 | 10 | 15 | 7 | 13 | 13 | 6 |
| Age (years) | 55.7 | 51.6 | 52.4 | 54.9 | 46.1 | 53.9 | 57.2 | 44.5* | 48.8 |
| (26–74) | (37–65) | (44–62) | (26–73) | (18–65) | (37–72) | (44–74) | (18–60) | (37–72) | |
| Gender (% M/F) | 69/31 | 64/36 | 40/60 | 80/20 | 73/27 | 57/43 | 69/31 | 77/23 | 67/33 |
| Height (cm) | 165.4 | 165.3 | 165.0 | 166.7 | 165.7 | 165.4 | 164.1 | 167.7 | 165.8 |
| (155–180) | (156–177.5) | (160–169) | (157–180) | (156–177.5) | (160–170) | (155–172.5) | (156–176) | (160–170) | |
| Weight (kg) | 65.2 | 63.2 | 58.2 | 66.2 | 63.1 | 63.4 | 65.0 | 64.9 | 61.2 |
| (55–77.1) | (49–81) | (49.1–62) | (52–77.1) | (49–81) | (49–85) | (52–77) | (52–74) | (49–85) | |
| BSA (m2) | 1.73 | 1.70 | 1.63 | 1.75 | 1.70 | 1.70 | 1.72 | 1.74 | 1.67 |
| (1.55–1.94) | (1.47–1.90) | (1.50–1.71) | (1.51–1.94) | (1.47–1.90) | (1.48–2.00) | (1.51–1.89) | (1.50–1.87) | (1.48–2.00) | |
*
P < 0.05, day 7 HomEM vs. HetEM. The values in parentheses indicate the data range. HomEM, homozygous extensive metabolizers; HetEM, heterozygous extensive metabolizers; PM, poor metabolizers; BSA, body surface area.